BLFS - BioLife Solutions, Inc.
| Previous Close | 15.45 |
| Open | 15.50 |
| Bid | 15.14 x 1100 |
| Ask | 15.18 x 800 |
| Day's Range | 14.85 - 15.50 |
| 52 Week Range | 9.15 - 22.44 |
| Volume | 175,512 |
| Avg. Volume | 176,015 |
| Market Cap | 306M |
| Beta (3Y Monthly) | 1.28 |
| PE Ratio (TTM) | 31.97 |
| EPS (TTM) | 0.47 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.00 |
- Simply Wall St.
Can BioLife Solutions, Inc. (NASDAQ:BLFS) Maintain Its Strong Returns?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Thomson Reuters StreetEvents
Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Biolife Solutions Inc Earnings Call
- PR Newswire
BioLife Solutions Announces Executive Appointments to Support Integration of Acquired Companies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced several executive appointments to further support the integration of Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, three companies acquired during 2019.
- American City Business Journals
Seattle has potential as a biotech hub, but more companies must stay here and grow
Seattle's biotech community has a reputation for developing companies that are eventually acquired and that has restricted its growth. But a few companies are well-positioned to change that narrative.
- PR Newswire
BioLife Solutions Acquires Custom Biogenic Systems
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially all of the assets of Custom Biogenic Systems, Inc. ("CBS"). CBS, a privately held company with operations located near Detroit, is a global leader in the design and manufacture of state-of-the-art liquid nitrogen laboratory freezers and cryogenic equipment.
- PR Newswire
BioLife Solutions Announces Third Quarter 2019 Financial Results
Third quarter revenue of $6.6 million , up 25% over the prior year Updates 2019 financial guidance to reflect CBS acquisition, introduces preliminary 2020 revenue guidance of $50 to $56 million Conference ...
- Simply Wall St.
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Creating Value For Shareholders?
Today we'll evaluate BioLife Solutions, Inc. (NASDAQ:BLFS) to determine whether it could have potential as an...
- Insider Monkey
BioLife Solutions, Inc. (BLFS): Hedge Fund Interest Cooling Off
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- PR Newswire
BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte's 2019 Technology Fast 500™
BOTHELL, Wash. , Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) , a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, ...
- PR Newswire
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
BOTHELL, Wash. , Oct. 31, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" ...
- Zacks
Medical Products Industry Outlook: Prospects Seem Promising
Medical Products Industry Outlook: Prospects Seem Promising
- TheStreet.com
A Quick Look at 2 Positive Looking Biotech Plays
In his "Homework" segment of Mad Money Friday night, Jim Cramer followed up on a few stocks that had stumped him during earlier shows. With its products in demand, Cramer said its valuation of 15 times earnings makes it cheap, although he cautioned that the company is small and the stock is speculative. Next, Cramer said that BioLife Solutions is another intriguing biotech play.
- PR Newswire
BioLife Solutions Awarded Three New Patents for Cryopreservation, Thawing and Cold Chain Transport Technologies
Intellectual Property Portfolio Growing with Inventions by Acquired Companies BOTHELL, Wash. , Oct. 14, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of ...
- PR Newswire
BioLife Solutions Announces Cell and Gene Therapy Bioproduction Innovation Accelerator
BOTHELL, Wash., Sept. 24, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with Casdin Capital, targeting early stage companies that are developing novel cell and gene therapy bioproduction tools. Mike Rice, BioLife Solutions CEO, remarked, "It is increasingly recognized that tools and technology for bioproduction are critical for the successful development and delivery of cell and gene therapies.
- GlobeNewswire
iVexSol Announces $2M in Seed Funding
BOSTON, Sept. 24, 2019 -- iVexSol, a newly formed viral vector manufacturing company, today announced $2.0 million in new convertible debt funding led by Casdin Capital, LLC.
- PR Newswire
BioLife Solutions Announces New evo® Cold Chain Customers
BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have adopted the evo cold chain management system in clinical trials targeting cancer and other leading causes of death. The evo system was designed by SAVSU Technologies, which was acquired by BioLife in August 2019. New evo customers joining the previously announced Mustang Bio and Novartis include Adaptimmune, Autolus, Janssen, KBI Pharma, Nanjing Legend and Tessa Therapeutics.
- GuruFocus.com
Biolife Solutions Inc (BLFS) President & CEO Michael Rice Sold $553,992 of Shares
President & CEO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Michael Rice (insider trades) sold 28,571 shares of BLFS on 09/11/2019 at an average price of $19.39 a share. Continue reading...
- GuruFocus.com
Biolife Solutions Inc (BLFS) CFO Greef Roderick De Sold $593,400 of Shares
CFO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Greef Roderick De (insider trades) sold 30,000 shares of BLFS on 09/06/2019 at an average price of $19.78 a share. Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of BLFS earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Biolife Solutions Inc Earnings Call
- PR Newswire
Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio ...
- PR Newswire
BioLife Solutions Strengthens Sales Team with Key Leadership Additions
BOTHELL, Wash. , Aug. 28, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, ...
- PR Newswire
BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
BOTHELL, Wash. , Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class ...
Motley FoolBiolife Solutions Inc (BLFS) Q2 2019 Earnings Call Transcript
BLFS earnings call for the period ending June 30, 2019.
- PR Newswire
BioLife Solutions Announces Second Quarter 2019 Financial Results
- Record quarterly revenue of $6.7 million , up 29% over the prior year - Updates 2019 financial guidance to reflect Astero and SAVSU contributions - Conference Call and Webcast Begin at 4:30 pm Eastern ...
- PR Newswire
BioLife Solutions Completes Acquisition of SAVSU Technologies
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies. The acquisition is expected to further strengthen BioLife's position as a leading supplier of disruptive, enabling solutions used in the manufacture, storage and distribution of cell and gene therapies.
